ROCKVILLE, Md., Nov. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences, which will each be held in a virtual meeting format:
Barclays Gene Editing & Gene Therapy Summit Presentation: Monday, November 15, 2021, at 1:30 p.m. ET
Piper Sandler 33rd Annual Virtual Healthcare Conference Date: December 2, 2021 Recorded Fireside Chat will be available: Monday, November 22, 2021, at 10:00 a.m. ET
A live webcast of the Barclays presentation and the recording of the Piper Sandler fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com for approximately 30 days following the events.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Tricia Truehart Investor Relations and Corporate Communications 347-926-7709 [email protected]